Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7,717.00
Bid: 7,724.00
Ask: 7,727.00
Change: 0.00 (0.00%)
Spread: 3.00 (0.04%)
Open: 7,690.00
High: 7,743.00
Low: 7,668.00
Yest. Close: 7,735.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

AstraZeneca Covid-19 vaccine clinical trial readout may arrive in mid-November, Jefferies says

Fri, 23rd Oct 2020 11:12

(Sharecast News) - Analysts at Jefferies estimated that an initial read-out on AstraZeneca and Oxford University's ongoing late-stage trial of its Covid-19 vaccine might ready towards the middle of November.
The broker arrived at that conclusion using what it described as a "back-of-the-envelope statistical analysis", under the assumption that the vaccine would prove 60% effective.

They also pointed out the possibility that the vaccine, AZD 1222, could prove better at moderating symptoms rather than preventing them altogether, which would make it harder to obtain a successful readout.

According to the US Food and Drug Administration, efficacy of 50% or greater was necessary in order for it to grant so-called Emergency Use Authorisation for ASD 1222.

If the vaccine's efficacy was closer to 50%, then the headline efficacy data could be available in December.

Nevertheless, they cautioned that they had also had to make various other assumptions, because they did not have access to AstraZeneca's detailed statistical analysis plan.

Hence, they had used what had been disclosed for the US clinical trial of the same drug as a starting point.

Another assumption was that the rate of infections in the UK would continue to rise, with the seven-day moving average having already done so, from roughly 3,700 cases per day in mid-September to above 16,000 at present.

"We see a risk the vaccine ameloriates infections and the risk of transmission but perhaps has less effect on initial presentation of symptoms, suggesting a benefit to society but raising the bar for a successful readout."

More News

TOP NEWS: PM Johnson confirms England lockdown easing on May 17

TOP NEWS: PM Johnson confirms England lockdown easing on May 17

10 May 21 18:55

Amgen notes AstraZeneca makes US biologics application for asthma drug

Amgen notes AstraZeneca makes US biologics application for asthma drug

10 May 21 17:24

UPDATE 1-AstraZeneca reaches vaccine shipping milestone as EU sues again

(adds legal case, duration of contract)By Francesco GuarascioBRUSSELS, May 10 (Reuters) - AstraZeneca Plc has delivered 50 million doses of its COVID-19 vaccine to European Union countries, according to EU supply data, a milestone the company had ...

10 May 21 17:12

AstraZeneca finally reaches vaccine shipping milestone to EU that was due in January

By Francesco GuarascioBRUSSELS, May 10 (Reuters) - AstraZeneca Plc has delivered 50 million doses of its COVID-19 vaccine to European Union countries, according to EU's latest supply data, a milestone it was originally due to hit in January.Repeat...

10 May 21 16:37

EU to launch new legal action against AstraZeneca over vaccine deliveries

BRUSSELS, May 10 (Reuters) - The European Commission will start on Tuesday a second legal case against AstraZeneca over its delayed deliveries of COVID-19 vaccines, a spokesman for the EU executive said on Monday.The move is mostly procedural afte...

10 May 21 16:11

UPDATE 1-One AZ COVID-19 vaccine dose gives 80% lower death risk - English data

(Adds details, quote)LONDON, May 10 (Reuters) - Data from the rollout of AstraZeneca's COVID-19 vaccine shows one dose of the shot results in 80% less risk of death from the disease, Public Health England said on Monday.It also said protection aga...

10 May 21 16:07

AstraZeneca plan to beef up CEO Soriot's pay packet faces scrutiny at AGM

LONDON, May 10 (Reuters) - A number of investor advisory groups have called on AstraZeneca shareholders to oppose plans to increase Chief Executive Pascal Soriot's pay package when the COVID-19 vaccine maker holds its annual meeting on Tuesday.As...

10 May 21 13:51

Europe dares to reopen as 200 millionth vaccine dose delivered

By Michael Gore and Estelle ShirbonMADRID/LONDON, May 10 (Reuters) - As its vaccination drive reaches a third of adults and COVID-19 infections ease, Europe is starting to reopen cities and beaches, raising hopes that this summer's holiday season ...

10 May 21 13:41

Europe dares to reopen as 200 millionth vaccine dose delivered

By Michael Gore and Estelle ShirbonMADRID/LONDON, May 10 (Reuters) - As its vaccination drive reaches a third of adults and COVID-19 infections ease, Europe is starting to reopen cities and beaches, raising hopes that this summer's holiday season ...

10 May 21 13:41

Monday broker round-up

(Sharecast News) - St Modwen: Liberum downgrades to hold with a target price of 542p.

10 May 21 13:05

Italy's Lazio region urges people to take AstraZeneca, J&J shots

ROME, May 10 (Reuters) - Italy's Lazio region, centred on the capital Rome, is urging people to book AstraZeneca and Johnson & Johnson COVID-19 shots, which have fallen out of favour with some residents over worries about possible side effects.Li...

10 May 21 12:52

Norway's committee recommends dropping AstraZeneca, J&J jabs

Norway's committee recommends dropping AstraZeneca, J&J jabs

10 May 21 12:08

Poland to shorten gap between COVID vaccine doses

WARSAW, May 10 (Reuters) - Poland will shorten the gap between doses for Pfizer, Moderna and AstraZeneca COVID-19 jabs, the minister responsible for Poland's vaccination programme said on Monday.The gap between doses for the Moderna and Pfizer vac...

10 May 21 11:13

UPDATE 1-GAVI in talks with China's Sinopharm, other vaccine makers for COVAX doses

(Adds details, background)GENEVA, May 10 (Reuters) - The GAVI Vaccine Alliance is in talks with COVID-19 vaccine manufacturers including China's state-owned Sinopharm to expand the COVAX pipeline and secure doses for distribution, a GAVI spokeswom...

10 May 21 10:13

Germany says reports of new side affects do not impact AstraZeneca vaccine recommendation

BERLIN, May 10 (Reuters) - Germany has no findings that would change its recommendation on the use of AstraZeneca's COVID-19 vaccine following reports of a rare nerve-degenerating disorder in people who received the shot, health minister Jens Spa...

10 May 21 09:21

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.